Home Blog of Signal Transduction Proteases Cathepsin B

Category

Archives

Popular Post

ESKM, a novel therapeutic agent for sensitive and resistant PH+ leukemias

The mechanism of resistance to JAK2 inhibitor in myeloproliferative neoplasms patients

Effects of PARP inhibitors in BRCA gene-mutated ovarian cancer

DASATINIB; An inhibitor of Receptor Tyrosine Kinase

GP130/JAK/STAT3 signaling pathway induces multiple myeloma

Cathepsin B

Molecular Features of CA-074 pH-Dependent Inhibition of Cathepsin B

280 views | Jun 08 2023

The study investigated the pH-dependent inhibitory properties of CA-074, a selective inhibitor of cathepsin B, and found it to be more effective at inhibiting cathepsin B at an acidic pH of 4.6 with nM potency, while maintaining its specificity for cathepsin B over other cysteine cathepsins under both acidic and neutral pH conditions. [Read the Full Post]

Apigenin Alleviated High-Fat-Diet-Induced Hepatic Pyroptosis by Mitophagy-ROS-CTSB-NLRP3 Pathway in Mice and AML12 Cells

186 views | Jun 08 2023

This passage describes a study on the effects of apigenin on liver injury caused by a high-fat diet and palmitic acid-induced pyroptosis in liver cells through the mitophagy-ROS-CTSB-NLRP3 pathway. [Read the Full Post]

Phytochemical characterization, antioxidant activity and antihypertensive evaluation of Ocimum basilicum L. in l-NAME induced hypertensive rats and its correlation analysis

291 views | Jun 05 2023

The study found that Ocimum basilicum Linn. leaves extracts have potential as antihypertensive drugs due to their bioactive metabolites, with phenolic compounds playing a role in inhibiting l-Name induced hypertension and flavonoids contributing to antioxidant activities. [Read the Full Post]

BC-1215 inhibits ATP-induced IL-1β secretion via the FBXL2-mediated ubiquitination and degradation of not only NLRP3, but also pro-IL-1β in LPS-primed THP-1 cells

154 views | May 10 2023

BC-1215, an inhibitor of FBXO3, suppresses ATP-induced IL-1β secretion in LPS-primed THP-1 cells via the FBXL2-mediated ubiquitination and degradation of NLRP3 and pro-IL-1β, making FBXO3 a potential therapeutic target for inflammatory diseases. [Read the Full Post]

Neutralization of NET-associated human ARG1 enhances cancer immunotherapy

99 views | Apr 09 2023

The study investigates the role of neutrophil extracellular traps (NETs) and cathepsin S (CTSS) in regulating the activity of arginase 1 (ARG1) in pancreatic ductal adenocarcinoma (PDAC) and suggests the potential of targeting extracellular ARG1 with monoclonal antibodies as a therapeutic approach for PDAC in combination with immune checkpoint inhibitors. [Read the Full Post]

Upfront autologous haematopoietic stem-cell transplantation versus carfilzomib-cyclophosphamide-dexamethasone consolidation with carfilzomib maintenance in patients with newly diagnosed multiple myeloma in England and Wales (CARDAMON): a randomised, phase 2, non-inferiority trial

439 views | Dec 23 2022

Kwee Yong et al. thought that KCd did not meet the criteria for non-inferiority compared with autologous HSCT, but the marginal difference in progression-free survival suggested that further studies were warranted to explore deferred autologous HSCT in some subgroups. [Read the Full Post]

Construction and evaluation of detachable bone-targeting MOF carriers for the delivery of proteasome inhibitors

476 views | Jun 17 2022

Hongbing Yang et al. provided a potential cascade targeting strategy for improving the delivery effects of bone targeted nanoparticles for the delivery of proteasome inhibitors. [Read the Full Post]

SLFN11 biomarker status predicts response to lurbinectedin as a single agent and in combination with ATR inhibition in small cell lung cancer

652 views | Apr 27 2022

Kiran Kundu et al. provided a rationale for lurbinectedin in combination with ATR inhibitors to overcome resistance in SCLC with low SLFN11 expression. [Read the Full Post]

Outcome of COVID-19 infection in 50 multiple myeloma patients treated with novel drugs: single-center experience

1440 views | Jul 27 2021

Marta Krejci et al. found that the course of COVID-19 disease in MM pts was mostly moderate or serious with 56% of hospitalizations and 18% of deaths. [Read the Full Post]

Phase 1 study of the ATR inhibitor berzosertib (formerly M6620, VX-970) combined with gemcitabine ± cisplatin in patients with advanced solid tumours

1118 views | Jun 02 2021

Mark R Middleton et al. found that Berzosertib + gemcitabine was well tolerated in patients with advanced solid tumours and showed preliminary efficacy signs. [Read the Full Post]